Advertisement
Advertisement
U.S. markets open in 8 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

La Jolla Pharmaceutical Company (LJPC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.19-0.02 (-0.32%)
At close: 04:00PM EDT
6.21 +0.02 (+0.32%)
After hours: 05:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • American City Business Journals

    Biotech M&A returns as Vertex, Innoviva make buys

    Come, thou long-expected M&A. On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions. Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC).

  • American City Business Journals

    How this Peninsula company is turning lung drug royalties into acquisitions

    With the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another.

  • Benzinga

    Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

    Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. The deal consideration of $6.23 per share in cash has an implied enterprise value of approximately $149 million. The FDA approved La Jolla's lead

Advertisement
Advertisement